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Expression of apolipoprotein B epitopes in low density lipoproteins of
hemodialyzed patients. Serum and isolated low-density lipoprotein
(LDL) composition abnormalities were investigated in 20 hemodialyzed
patients with chronic renal failure and 15 healthy normolipidemic
subjects for comparison. LDL apolipoprotein B (apo B) epitope acces-
sibility was determined by the use of seven monoclonal antibodies
(Mabs). These Mabs recognize fragments on the N-terminal part of apo
B (Mabs Bi, B4), on the middle part (Mab BL7), on the C-terminal
(Mabs BA!!, BL3), and the two remaining Mabs recognize conforma-
tional epitopes of apo B (BL5, DA7). Mab BA!! recognizes a fragment
of apo B which interacts with the B/E receptor. In hemodialyzed
patients, LDL content of triglycerides (P < 0.001) and apo CIII (P <
0.005) was increased, while cholesteryl esters (P < 0.005) were de-
creased. The accessibility of BL5 epitopes of LDL apo B was enhanced
(P < 0.05), while BAIl epitope expression was decreased (P < 0.01).
The conformation of patients' LDL (CRF-LDL) was probably abnor-
mal and seemed to be related to some modification of the lipidic
environment. It is important to consider a structural modification as it
alters the B/E receptor recognition domain of apo B. These results
confirm LDL abnormalities in hemodialyzed patients and suggest a
possible modification of the recognition of the LDL by cells.
Clinical and experimental studies have established that ele-
vated plasma low-density lipoproteins (LDL) are associated
with atherogenesis [1, 2]. The most characteristic features of
the atherosclerotic lesions are the accumulation of macro-
phages in the intima of the arterial wall which are loaded with
cholesteryl esters and called "foam cells" [3]. In vitro studies
have shown that only modified LDL could accumulate in
macrophages via the scavenger receptor [4, 5]. The clearance of
native LDL is mediated by the B/E receptor described by
Brown and Goldstein [61, which is, in contrast to the scavenger
receptor, down-regulated. The most current modification of
LDL in vjvo could be their oxidation. Indeed, oxidized LDL
have been extracted from aortic lesions [7] and autoantibodies
against oxidized LDL have been found in human sera [8]. The
oxidative modification occurs especially in microdomains of the
intima, sequestered from plasma antioxidants. For some au-
thors, cardiovascular disease is a premature and frequent
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complication in patients with chronic renal failure treated by
hemodialysis [9—12], and many studies have demonstrated that
lipid abnormalities occur in these patients. The most common
abnormality is hypertriglyceridemia associated with an accumu-
lation of very low-density lipoprotein (VLDL). High-density
lipoprotein (HDL) cholesterol is decreased and LDL choles-
terol is usually normal [13, 14]. The hypertriglyceridemia ob-
served does not really explain the increased risk of ischemic
heart disease, but could participate therein with subtle changes
in lipoprotein particles such as LDL or HDL [15]. It could be
possible that LDL contributes to the phenomenon of athero-
sclerosis by modification of apolipoprotein B (apo B) on its
surface, which would lead to a less efficient recognition by the
B/E receptor of the cells. These modifications could be related
to altered expression of apo B epitopes on LDL, to changes in
the lipid composition [16, 17], and/or the size and density of the
LDL [18].
We investigated the accessibility of LDL-apo B 100 epitopes
to monoclonal antibodies (BL3, BL5, BL7, Bi, B4, DA7,
BAll) and the possible relationship between accessibility of
apo B epitopes and the composition of the LDL isolated from
hemodialyzed patients.
Methods
Patients
Twenty patients (10 women and 10 men) with chronic renal
failure (CRF) receiving hemodialysis, and aged 51 12 years
(range 27 to 70 years) were investigated. Sixteen patients were
on hemodialysis twice a week, and four patients were hemodi-
alyzed three times a week, with a mean duration of 15 to 18
hours a week. Acetate-buffered dialysates were used with
polysulfone dialyzers for nine patients, polyacrylonitrile for
eight patients and cuprophane for three patients. The renal
diagnosis showed chronic glomerulonephritis in eleven pa-
tients, chronic interstitial nephropathy in three patients, poly-
cystic kidney disease in two patients, two with vascular ne-
phropathy, two with reflux nephropathy, and none was
nephrotic. They were undergoing hemodialysis for 7.2 4.4
years. The patients were on an ad libitum diet and the individual
food intake was not monitored. Smokers, patients with disor-
ders other than CRF or with clinical evidence of coronary
artery disease were excluded from the study. One patient was
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treated with erythropoietin, two others with beta blocking
agents and four received angiotensin converting enzyme inhib-
itors for hypertension. Patients with and without treatment, as
well as patients dialyzed with polyacrylonitrile or polysulfone
membranes were compared, but no significant difference could
be found in any variable between the two groups of patients. All
subjects were within 10% of ideal body weight.
Controls
Fifteen Caucasian control subjects were recruited from the
Center for Preventive Medicine (Pasteur Institute, Lille,
France). They were in good health and had been taking no
medication for at least three months. Their physical examina-
tion was normal and they had no familial history of cardiovas-
cular disease. All control subjects had normal lipid levels
(cholesterol below 200 mg/dl and triglycerides below 150 mgldl).
Mean age and sex ratio were in the same range as those of the
patients.
LDL isolation
For all subjects, blood samples (20 ml) were collected in
vacutainer tubes after an overnight fast and before the hemo-
dialysis session for patients. The samples were obtained before
any heparin was administered. After centrifugation (3,000 g,
4°C, 20 mm) preservatives were added to prevent degradation
of lipoproteins. These additives (and their final concentrations)
were as follows: EDTA (0.27 mM), cis-amino-caproic acid (0.9
mM), chloramphenicol (0.6 mM), and glutathion (0.3 mM) [19].
LDL were isolated from sera of the patients and the control
subjects.
LDL were obtained by sequential ultracentrifugation in a
Beckman 50.2Ti rotor [20]. The density range was chosen
between 1.025 and 1.050 kg/liter to prevent contamination by
intermediate-density lipoproteins (IDL) or Lp(a). Isolated
LDLs were dialyzed against phosphate isotonic saline buffer
(PBS, pH = 7.4) containing EDTA 0.1 g/liter, and their purity
was assessed by non-denaturing discontinuous gradient poly-
acrylamide gel electrophoresis [21].
LDL obtained from patients and controls were respectively
designated as CRF-LDL and C-LDL.
From a pool of 42 fresh normolipidemic sera which also
contained preservatives as above, a LDL standard batch was
likewise purified. It was stored at 4°C in sterile aliquots under
nitrogen gas. We observed no proteolytic degradation or oxi-
dative processes occurring throughout the three months of the
study.
Biochemical analyses
Analyses were made on fresh serum or on LDL stored at 4°C
for no longer than three days.
Total cholesterol (TC), triglycerides (TG), free cholesterol
(FC) and phospholipid (PL) content in sera and/or LDL prep-
arations were determined by enzymatic methods (Boehringer-
Mannheim, Mannheim, Germany). HDL cholesterol was deter-
mined in the supernatant after precipitation of apo B-containing
proteins by the addition of sodium phosphotungstate-MgCl2
(Biomërieux, France). Cholesteryl esters (CE) in LDL were
calculated by the formula: CE = (TC — FC) x 1.68. Serum
LDL cholesterol was calculated by the formula of Friedewald,
Levy and Fredrickson [22].
Apolipoproteins (apo) A!, All, B, CIII, and E were measured
by a non-competitive enzyme-linked immunoassay (ELISA) on
microtiter plates (Costar, Cambridge, Massachusetts, USA), as
described earlier [23—25]. The protein content of LDL was
measured by a modified Lowry procedure [26] using bovine
serum albumin (BSA) as a standard.
Monoclonal anti-apo B antibodies
The monoclonal antibodies (Mabs) used in the present study
were BL3, BL5 and BL7, produced in mice by the Research
Center Clin-Midy (Montpellier, France) [16] and B1, B4, DA7
and BA! 1, produced in rats by University of Louvain (Bel-
gium). All these antibodies have been well-characterized [27—
29].
The localization of their specific epitopes along the apo B
molecule has been mapped [30] between residues 405-539 (Mab
BI), 1854-1879 (Mab B4), 2239-2376 (Mab BL7) and at residues
3506 (MabBA1!) and 4355 (Mab BL3).
Mabs BL5 and DA7 failed to react with any fragments,
suggesting they recognize conformationally expressed epitopes.
Among all these antibodies, Mab BA1 1 is the only one able to
decrease the uptake and degradation of 1251-labeled LDL by the
LDL receptor cells [16].
Jodination of LDL
Some aliquots of LDL standard were radioiodinated with Na
125j according to a procedure previously described [3!]. The
final specific activity varied between 400 and 650 cpm/ng of
protein, and more than 90% of the radioactivity was precipita-
ble by 10% trichloroacetic acid.
Solid phase radioimmunoassay
To determine the expression of antigenic determinants of
LDL preparations we performed a solid phase radioimmunoas-
say in which the lipoproteins were assayed in competitive
displacement assays on microtiter plates (Costar) as follows.
Flexible PVC plates with 96 wells of 270 d capacity were
coated with 100 jd of each Mab solution (25 pg/mI of PBS) for
three hours at room temperature. After emptying, the wells
were washed three times with PBS and then incubated with
PBS containing 10 g/liter of BSA (BSA-PBS) for one hour at
room temperature to saturate extra-binding sites on the plastic.
After removal of this blocking solution, increasing dilutions of
competitors (each LDL preparation and LDL standard ex-
pressed as protein content from 1.56 to 100 pg/ml), were added
in 50 j.d BSA-PBS and immediately followed by a constant
amount of 1251-labeled LDL (150,000 cpm in 50 1d of BSA-PBS).
After incubation overnight at room temperature, the wells
were emptied, rinsed three times with PBS, sliced and counted
in a gamma spectrometer [16]. All assays were carried out in
triplicate.
Results were plotted as B/B0 ratios versus lipoprotein con-
centration (B and B0 are specific cpm bound in presence or
absence of competitor, respectively). The apparent apo B
contents were calculated from competitive displacement curves
as the number of epitopes required for the displacement of 50%
of the normal '251-labeled LDL. The results were expressed as
a percentage of the LDL standard to which an arbitrary
expression of 100% was assigned. Therefore, a percentage
value above 100 indicates that more LDL were needed to
1362 Reade ef a!: Apo B epitopes of LDL
Table 1. Biochemical data of sera from patients (CRF) and control
subjects (C)
CRF C P
Total cholesterol l%.5 49.7 178.6 31.0 NS
Triglycerides 132.5 67.5 89.1 48.7 NS
Phospholipids 198.2 48.6 197.6 35.2 NS
HDL cholesterol 33.4 7.2 45.0 6.1 <0.001
LDL cholesterol 135.9 44.8 115.5 25.7 NS
Apo B 130.4 38.5 99.6 14,0 <0.05
Apo CIII 12.3 6.7 2.7 1.1 <0.001
Apo E 4.2 1.8 4.3 2.0 NS
Apo Al 125.7 23.7 164.0 22.5 <0.001
Apo All 21.9 5.6 21.0 5.3 NS
Data are given in mg/dl and correspond to means
hemodialyzed patients with chronic renal failure (CRF) and 15 control
subjects (C). P values represent significant levels; NS is not significant.
achieve the same displacement of the labeled LDL standard
ligand and reflected a decreased accessibility of the measured
epitope.
The displacement curves were then linearized by logit-log
transformation of the data and slopes were calculated. They
corresponded to the apparent aflinity of the different LDL
preparations for each antibody [32].
The within-run assay variations, estimated by triplicate anal-
ysis [32] of the LDL standard, are respectively: 5.4%, 9.0%,
6.1%, 6.7%, 5.9%, 3.5% and 3.5% for Mabs B!, B4, BAll,
DA7, BL3, BL5 and BL7.
Statistical analysis
A statistical comparison of data obtained between the pa-
tients and the control subjects was performed using the Mann-
Whitney U test.
The correlations between lipid or protein parameters and the
apparent apo B content of LDL were tested by using a
Spearman rank simple correlation test.
Results
Lipids and apolipoproteins in sera
The serum lipid and apolipoprotein parameters from the
patients and the control subjects were measured. Table 1 shows
significantly higher apo CIII (P < 0.001) and apo B (P < 0.05)
levels in patients. Total triglycerides, cholesterol and LDL
cholesterol levels were also increased in patients but the
difference with the controls was not significant.
HDL cholesterol and apo A! were lower (P < 0.001) in
patients when compared to the control group.
Phospholipids, apo E and apo Al! were identical in both
groups.
Lipids and apolipoproteins in LDL
Table 2 shows the chemical composition of the LDL prepa-
rations. The results are expressed as percentages, calculated as
the fraction of the total weight for the lipids and the fraction of
the total proteins for the apolipoproteins. The percentages of
triglycerides (P < 0.001) and apo CIII (P <0.005) are increased
in CRF-LDL, while cholesteryl ester (P < 0.005) is decreased.
sn for 20
Table 2. Biochemical composition of CRF-LDL and C-LDL
CRF-LDL P C-LDL
Triglyceride? 9.3 3.4 <0.001 4.4 0.8
Phospholipidsa 22.1 6.5 NS 19.8 1.6
Free cholesterola 11.0 3.6 NS 10.7 1.6
Cholesteryl estersa 36.5 5.3 <0.005 41.0 1.1
Proteinsa 21.1 2.5 <0.001 24.1 1.2
Apo B"
Apo CIII"
Apo Eb
99.3 0.4
0.42 0.37
0.28 0.16
NS
<0.005
NS
99.4 0.6
0.10 0.10
0.50 0.53
Results for lipids are expressed as percentages of LDL massa and for
apolipoproteins as percentages of total protein contentb. Data corre-
spend to means SD for LDL from 20 patients (CRF-LDL) and IS
control subjects (C-LDL). P values represent significant levels; NS is
not significant,
Table 3. Immunochemical reactivity of LDL preparations
Monoclonal
antibodies CRF-LDL P C-LDL
BI 103 28 NS 103 21
B4 113±44 NS 103±17
DA7 104±22 NS 104±10
BL3 103 32 NS 108 9
BL5 82 28 <0.05 100 4
BL7 102 27 NS 108 9
BAlI Ill 15 <0.01 100 3
Results are expressed as a percentage of LDL standard to which an
arbitrary expression of each epitope was assigned as 100%.
Data are the mean apparent Apo B content SD for LDL from 20
patients (CRF-LDL) and 15 control subjects (C-LDL) calculated from
competitive displacement curves as described in Methods section. They
are the compiled results of triplicate experiments. P values represent
significant levels; NS is not significant.
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No significant difference between the slopes obtained for
CRF-LDL and C-LDL was observed (results not shown). This
indicates that C-LDL or CRF-LDL epitopes have the same
apparent affinity for each antibody, demonstrating a good
homogeneity of LDL preparations.
Table 3 shows that the number of BL5 epitopes required for
the displacement of 50% of the normal '251-labeled LDL is
lower with the CRF-LDL than with the C-LDL (82 28% and
100 4%, respectively, P < 0.05).
In contrast, the number of BA1 1 epitopes required is higher
(111 15% and 100 3%, respectively, P < 0.01). This
indicates that CRF-LDL apo B shows a deficit in the immuno-
logical accessibility of BA 11 epitope and an increase in the
accessibility of BL5 epitope.
Relationship between LDL composition and immunoreactivily
A negative correlation coefficient between any apparent apo
B content and any lipid or protein content indicates that the
higher the level of one of these biochemical components, the
less important the apparent apo B content is and therefore the
more accessible is the epitope recognized by the Mab, and
vice-versa.
When patients and controls are grouped together, significant
correlations were found between the apparent apo B content,
measured with Mab BI and the protein fraction (r = +0.63; P <
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0.05) and apo CIII content (r = +0.57; P < 0.05), between the
apparent content of apo B measured with Mab BL3 and apo
CIII content (r = +0.61, P < 0.01) and Mab BAll and
triglyceride content (r = +0.35, P < 0.02).
Discussion
In the present study, we report abnormalities in LDL apo B
immunological accessibility in patients with chronic renal fail-
ure undergoing hemodialysis. These abnormalities occur de-
spite a normal apo B content in LDL but could be related to
changes in LDL apo CIII and triglyceride contents.
We confirm an increase of apo CIII in the serum of chronic
hemodialysis patients and a decrease of HDL cholesterol and
apo Al, as previously reported [33—36]. In addition, we show an
increase of apo B in our patients, despite the lack of coronary
heart disease history [19].
Many studies have supported the evidence that elevated
levels of LDL cholesterol and decreased levels of HDL choles-
terol are associated with an increased vascular risk. The role of
elevated levels of plasma triglycerides as an independent risk
factor for ischemic heart disease remains nevertheless contro-
versial [15].
Premature mortality of CRF patients from ischemic heart
disease is well-documented [9, 37, 38], although the literature
mentions normal levels of LDL cholesterol and apo B [19, 34,
39]. Abnormal LDL may contribute to this phenomenon, since
it has been shown that modifications in lipid [40] and apoli-
poprotein [41] LDL composition may alter LDL binding affinity
to the B/E receptor [41, 42] and may alter LDL degradation by
cells [40].
In agreement with our results, previous studies have shown
several abnormalities in LDL composition in chronic uremia, in
that they are enriched in triglycerides but have normal or
slightly increased apo B content [13, 43]. The major protein
disturbance is an increase of apo CIII content [33]. These
abnormalities suggest a slowing down in the catabolism of
triglyceride-rich lipoproteins such as VLDL and IDL to give an
"immature form" of LDL, enriched in triglycerides and apo
CIII. In addition, in accordance with other reports [44, 45] we
observed a decrease in cholesteryl ester content in CRF-LDL
(P < 0.005) as if there was an acceleration of the transfer of
triglycerides and esterified cholesterol between VLDL and
LDL, as in the case of hypertriglyceridemic subjects [46]. This
hypothesis is supported by the fact that authors reported that
the esterified cholesterol/triglyceride ratio in VLDL is higher in
uremic patients than in control subjects [44].
There are numerous reports in the literature suggesting that
plasma LDL could undergo "limited" degrees of modification
that would be no consequence while still in the vascular space.
Yet when such LDL enters the intima, it might then be
"primed" for more rapid oxidative modification mediated by
cells. Such slight modifications could not be detected by
changes in LDL agarose mobility or apo B SDS-PAGE migra-
tion but, as reported by Zawadzki and Milne Marcel [47], they
could be revealed by changes in the immunoreactivity of LDL
studied with appropriate Mabs specific for apo B epitopes.
In a previous paper, we studied the immunological accessi-
bility of apo B epitopes in sera of hemodialyzed patients in
comparison with atherosclerotic subjects, using monoclonal
antibodies BL3, BLS and BL7. We showed that the expression
of BL7 epitopes was significantly increased in the group of
hemodialyzed patients, whereas BL3 and BL5 epitopes were
increased in patients with coronary artery disease [48]. Over-
expression of BL7 epitopes was probably related to VLDL apo
B since we do not observe this overexpression in LDL apo B in
the present study.
In this study, we have found an overexpression of BL5
conformational epitopes on the LDL from patients. This spe-
cific immunomarker has been already found to be increased in
the serum of patients with coronary artery disease, therefore
reflecting conformational changes of apo B containing particles
in such patients, even if they were normolipidemic [49].
However, our patients present no clinical evidence of coro-
nary artery disease but they have LDL with an altered compo-
sition. Numerous studies have already shown, in this way, a
lipid dependence of the major epitopes and especially cho-
lesteryl ester, which is important for the expression of the
epitope recognition receptor of apo B [17].
More interesting is the decrease of BA! 1 epitope expression,
because its specific Mab recognizes a protein fragment of apo B
which interacts with the B/E receptor. Moreover, the cellular
binding of LDL may be related to the disposition of apo B
epitopes on their surface, as in the case of hypertriglyceridemic-
LDL. Indeed, after hypolipidemic therapy, parallel changes
were observed in the cell reactivities and immunoreactivities of
LDL preparations; when the triglyceride content of LDL de-
creased, fibroblast association and degradation increased, and
expression of an epitope in the binding site of apo B was
enhanced [17], and conversely with LDL enriched in triglycer-
ides [50]. Other authors demonstrate that affinities of interac-
tions between LDL and the BIE receptor of fibroblasts were
decreased with increasing LDL-triglyceride enrichment, even
though the epitopes relatively close to the LDL receptor
recognition domain were apparently not affected [51]. Hyper-
triglyceridemic LDL are less effective in down-regulation of
LDL receptor activity and inhibition of sterol synthesis by
human skin fibroblasts in culture [40]. Moreover, the enrich-
ment of LDL in apo CIII decreases the affinity and the number
of binding sites of LDL to the HeLa cells [41]. The importance
of the lipid composition of lipoproteins in their metabolism is
demonstrated by the fact that hypertriglyceridemic VLDL, in
contrast to normal VLDL, can be taken up by the BIE receptor
of fibroblasts, despite a similar content in apo B and apo E [52].
Thus, CRF-LDL could be removed from the circulation less
effectively than normal LDL through a process mediated by the
BIE receptor, and then intercepted by the scavenger receptor of
macrophages.
This hypothesis should be further examined.
Conclusion
In summary, the main abnormalities in CRF-LDL composi-
tion are an enrichment in triglycerides and in apo CIII. Their
impoverishment in cholesteryl esters suggests an excessive
lipid transfer between the large pool of slow turnover VLDL
and LDL.
The abnormal composition of LDL could play a role in the
accelerated atherosclerosis in patients with chronic renal failure
on maintenance hemodialysis, because it could slow down the
catabolism of LDL by the B/E receptor and lead to their uptake
by the macrophages. Our data indicate that a region in the LDL
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receptor binding domain of apo B-100 is altered in hemodia-
lyzed patients, but it remains to be seen whether this modifica-
tion is sufficient to perturb the recognition of the LDL by the
cells.
Acknowledgments
This work was supported in equal parts by grants from the Regional
Council of Nord-Pas-de-Calais, 7, Square Morisson, 59014 Lille Cedex,
France and from the 'Ligue du Nord d'Hygiène Sociale," 19 bis rue
d'Inkermann, 59014 Lille Cedex, France. We gratefully acknowledge
Mrs. Carole Robin for secretarial help, Mr. Reginald Reade and Mr.
Paul Kelly for assistance in preparation of the text.
Reprint requests to Claude Cachera, Ph.D., Laboratoire de Recher-
che Néphrologique, CHU de Lille, Hôpital A. Calmetie, 59 037 Lille
Cedex, France.
References
1. KANNEL WB, CASTELLI WP, GoRDON J: Cholesterol in the pre-
diction of atherosclerotic disease. New perspectives on the
Framingham study. Ann Intern Med 90:85—91, 1979
2. CONSENSUS CONFERENCE STATEMENT: Lowering blood cholesterol
prevents heart disease. JAMA 253:2080—2086, 1985
3. BROWN MS, GOLDSTEIN JL: Lipoprotein metabolism in the mac-
rophage: implication for cholesterol deposition in atherosclerosis.
Annu Rev Biochem 52:223—261, 1983
4. HENRIKSEN T, MAHONEY EM, STEINBERG D: Enhanced macro-
phage degradation of biologically modified LDL. Arteriosclerosis
3:149—159, 1983
5. GOLDSTEIN JL, Ho YK, BASU SK, BROWN MS: Binding site on
macrophages that mediates uptake and degradation of acetylated
low density lipoprotein, producing massive cholesterol deposition.
Proc Nail Acad Sci USA 76:333—337, 1979
6. BROWN MS, GOLDSTEIN L: A receptor mediated pathway for
cholesterol homeostasis, Science 232:34—47, 1986
7. MORTON RE, WEST GA, HOFF HF: A low density lipoprotein sized
particle isolated from human atherosclerotic lesions is internalized
by macrophages via a non-scavenger-receptor mechanism. J Lipid
Res 27:1124—1134, 1986
8. PARUMS DV, BROWN DL, MITCHINSON MJ: Serum antibodies to
oxidized low-density lipoprotein and ceroid in chronic periaortitis.
Arch Pathol Lab Med 114:383—387, 1990
9. LAZARUS JM, LowalE EG, HAMPERS CL, MERRILL JP: Cardiovas-
cular disease in uremic patients on hemodialysis. Kidney mt
7(Suppl 2):l67—175, 1975
10. LINDNER A, CHARRA B, SHERRARD Di, SCRIBNER BH: Acceler-
ated atherosclerosis in prolonged maintenance hemodialysis. N
EngI J Med 290:697—701, 1974
II. LOWRIE EG, LAZARUS JM, MOCELIN AJ, BAILEY GL, HAMPEN5
CL, WILSON RE, MERRILL JP: Survival of patients undergoing
chronic hemodialysis and renal transplantation. N Engl J Med
288:863—867, 1973
12. JACOBS C, BRUNNER FP, CHANTLER C: Combined report on
regular dialysis and transplantation. Proc Eur Transplant Assoc
14:3, 1977
13. DRUEKET, LACOUR B, ROULLETJB, FUNK-BRENTANOJL: Recent
advances in factors that alter lipid metabolism in chronic renal
failure. Kidney mt 24(Suppl 16):Sl34—Sl38, 1983
14. RIESEN WF, M0RDA5INI R: Hyperlipidemia in renal failure. Phe-
notypes and pathogenetic mechanisms. Conir Nephrol 41:312—320,
1984
IS. HAMSTEN A: Hypertriglyceridemia, triglyceride-rich lipoproteins
and coronary heart disease. Clin Endocrino! Metabol 4:4:895—922,
1990
16. FIEVET C, DURIEUX C, MILNE R, DELAUNAY T, AGNANI 0, BAZIN
H, MARCEL Y, FRUCHART JC: Rat monoclonal antibodies to human
apolipoprotein B: Advantages and applications. J Lipid Res 30:
1015—1024, 1989
17. KLEINMAN Y, SCHONFELD G, GAVISH D, OSCHRY Y, EINSENBERG
S: Hypolipidemic therapy modulates expression of apolipoprotein
B epitopes on low density lipoproteins. Studies in mild to moderate
hypertriglyceridemic patients. J Lipid Res 28:540—548, 1989
18. TIKKANEN MJ, COLE TG, SCHONFELD 0: Differential reactivity of
human low density lipoproteins with monoclonal antibodies. J
Lipid Res 24: 1494—1499, 1983
19. AT-TMAN P0, ALAuPovic P, GUSTAFSON A: Serum apolipoprotein
profile of patients with chronic renal failure. Kidney liii 32:368—375,
1987
20. HAvEL Ri, EDER WA, BRAGDON JH: The distribution and chemi-
cal composition of ultracentrifugally separated lipoproteins in hu-
man serum, J Clin Invest 34:1345—1353, 1955
21. SEZILLE 0, FRUCHART JC, JAILLARD J, DEWAILLY P, DESREU-
MAUX C: Improved serum lipoprotein electrophoresis procedure in
polyacrylamide gradient gel. Biomedicine 23:315—317, 1975
22. FRIEDEWALD WT, LEVY RI, FREDRICKSON DS: Estimation of the
concentration of low-density lipoprotein cholesterol in plasma,
without use of the preparative ultracentrifuge. Clin Chem 18:499—
502, 1972
23, FRUCHART JC, FIEVET C, OUVRY D, KOFFIGAN M, BEUCLER I,
AYRAULT-JARRIER M, Du BARRY M, MARCOVINA S: Enzyme
linked immunoassay on microtiter plates for human apolipoprotein
B. Ric Clin Lab 3:569—574, 1984
24. PARSY D, CLAVEY V, FIEVET C, KOP.A I, DURIEZ P, FRUCHART JC:
Quantification of apolipoprotein CIII in serum by a non-competitive
immunoenzymometric assay. Clin Chem 31:1632—1636, 1985
25. FRUCHART JC, FIEVET C, PUCHOIS P: Apolipoproteins, in Methods
of Enzymatic Analysis (vol 8), edited by BERGMEYER HU, BERG-
MEYER J, GRASSL M, Weinheim, Verlag Chemie, 1985, pp. 126—138
26. MARKWELL MAK, MORAs SM, BIEBER LL, TOLBERT NE: A
modification of the Lowry procedure to simplify protein determi-
nation in membrane and lipoprotein samples. Anal Biochem 87:
206—210, 1978
27. LUYEYE I, FIEVET C, DUPONT JC, DUR1EUX C, SLIMANE N,
LECOCQ iF, DEMARQUILY C, FRUCHART JC: Human apolipopro-
tein B. Evidence for its immunochemical heterogeneity using
monoclonal antibodies and immunoenzymometric assay. Clin Bio-
chem 21:255—261, 1988
28. SALMON 5, GOLDSTEIN S, PASTIER D, THERON L, BERTHELIER M,
AYRAULT-JARRIER M, DUBARRY M, REBOURCET R, PAy B: Mono-
clonal antibodies to low density lipoprotein used for the study of
low and very-low-density lipoproteins in "ELISA" and immuno-
precipitation techniques. Biochem Biophys Res Commun 125:704—
711, 1984
29. BAZIN H, CORMONT F, DE CLERQ L: Rat monoclonal antibodies.
II. A rapid and efficient method of purification from ascitic fluid or
serum. J Immunol Meth 71:9—16, 1984
30. PEASE Ri, MILNE RW, JES5UP WK, LAW A, PROVOST P, FRU-
CHART JC, DEAN RT, MARCEL YL, SCoTr J: Use of bacterial
expression cloning to localize the epitopes for a series of monoclo-
nal antibodies against apolipoprotein B 100. JBiol Chem 1:553—568,
1990
31. BILHEIMER DW, EISENBERG 5, LEVY RI: The metabolism of very
low density lipoprotein proteins I. Preliminary in vitro and in vivo
observations. Biochim Biophys Ada 260:212—221, 1972
32. RODBARD D: Statistical quality control and routine data processing
forradioimmunoassays and immunoradiometric assays. Clin Chem
20:1255—1270, 1974
33. ATFMAN P0, ALAUPOVIC P, KNIGHT C, WANG CS, BASS H:
Apolipoprotein pattern in patients with chronic renal failure. Con-
trib Nephrol 41:328—331, 1984
34. PARSY D, DRACON M, CACHERA C, PARRA HJ, VANHOUTTE 0,
TACQUET A, FRUCHART JC: Lipoprotein abnormalities in chronic
haemodialysis patients. Nephrol Dial Transplant 3:51—56, 1988
35. DUVAL F, FROMMHERZ K, ATGER V. DRUEKE 1, LACOUR B:
Influence of end-stage renal failure on concentrations of free
apolipoprotein Al in serum. Clin Chem 35:963—966, 1989
36. HEUCIt CC, RITZ E: Hyperlipoproteinemia in renal insufficiency.
Nephron 25:1—7, 1980
37. KRAMER P, BROYER M, BRUNNER FP, BRYNGER H, DONCKER-
WOLCKE RA, JACOBS C, SELWOOD NH, WING AJ: Combined
report on regular dialysis and transplantation. Eur Proc Eur Dial
Transplant Assoc 19:4, 1982
38. BROYERM, BRUNNER FP, BRYNGER H, FASSBINDER W, GUILLOU
Reade et a!: Apo B epitopes of LDL 1365
PJ, OULES R, RizzoNi G, SELWOOD NH, WING AG: Demography
ofdialysis and transplantation in Europe. Nephrol Dial Transplant
1:1, 1986
39. GoNEN B, GOLDBERG AP, HARTE HR. SCHONFELD G: Abnormal
cell-interactive properties of low-density-lipoproteins isolated from
patients with chronic renal failure. Metabolism 34:1:10—14, 1985
40. KLEINMAN J, EISENBERG 5, OSCHRY Y, GAvI5H D, STEIN 0,
STEIN Y: Defective metabolism of hypertriglyceridemic low den-
sity lipoprotein in cultured human skin fibroblasts. J Clin Invest
75:1796—1803, 1985
41. AGNANI G, BARD JM, CANDELIER L, DELATTRE 5, FRUCHART JC,
CLAVEY V: Interaction of LpB, LpB:E, LpB:CIII and LpB:CIII:E
lipoproteins with the low density lipoproteins receptor of HeLa
cells. Arteriosclerosis Thromb 1:1021—1029, 1991
42. DONG LM, YAMAMURA T, YAMAMOTO A: Enhanced binding
activity of an apolipoprotein F mutant, apo ES, to LDL receptors
on human-fibroblasts. Biochem Biophys Res Commun 168:2:409—
414, 1990
43. ROBERT D, MORDASINI RC, RIE5EN W: Dyslipoproteinemia in
renal disease, in Human Plasma Lipoproteins (vol 3), edited by
FRUCHART FC, SHEPHERD J, Berlin, de Gruyter W, 1989, pp.
207—2 18
44. ATGER V, DUVAL F, FROMMHERTZ K, DRUEKE T, LACOUR B:
Anomalies in composition of uremic lipoproteins isolated by gradi-
ent ultracentrifugation: Relative enrichment of HDL in apolipopro-
tein CIII at the expense of apolipoprotein A-I. Atherosclerosis
74:75—83, 1988
45. DIEPLINGER H, SCHOENFELD PY, FIELDING Ci: Plasma choles-
terol metabolism in end-stage renal disease. J Clin Invest 77:1071—
1083, 1986
46. EISENBERG 5, DECKELBAUM R: Intravascular lipoprotein remodel-
ling: Neutral lipid transfer proteins, in Human Plasma Lipoproteins
(vol 3), edited by FRIJCHART JC, SHEPHERD J, Berlin, 1989, pp.
153—171
47. ZAWADZKI Z,Mii RW, MARCEL YL: Cu2 mediated oxidation
of dialyzed plasma: Effects on low and high density lipoproteins
and cholesteryl ester transfer protein. J Lipid Res 32:243—250, 1991
48. READER, EQUAGOO K, CACHERA C, DURIEZ P, DRACON M, BARD
JM, FIEVET C, BERTRAND M, TACQUET A, FRUCHART JC: Apoli-
poprotein B. Immunochemical heterogeneity in dialyzed patients
with chronic renal failure and patients with coronary artery steno-
sis. Am J Nephrol 9:2:110—114, 1989
49. FIEVET C, NU1-rENS MC, DUCIMETIERE P, FRUCHART JC, BER-
TRAND M, SALOMEZ JL: Relation of arteriographically defined
coronary artery disease to serum lipoprotein particles mapped with
monoclonal antibodies. Circulation 84:1:153—159, 1991
50. AVIRAM M, LUND-KATZ S. PHILLIPS MC, CHAIT A: The influence
of the triglyceride content of LDL on the interaction of apolipopro-
tein B-tOO with cells. J Biol Chem 263:32:16842—16848, 1988
51. KINOSHITA M, KRUL ES, SCHONFELD 0: Modification of the core
lipids of LDL produces selective alterations in the expression of
apo B-lOO epitopes. J Lipid Res 31:701—708, 1990
52. GIANTURCO SH, BROWN PB, GOTTO AM, BRADLEY WA: Recep-
tor-mediated uptake of hypertriglyceridemic very low density Ii-
poproteins by normal human fibroblasts. J Lipid Res 23:984—993,
1982
